Stem cell therapy using autologous stem cells to treat degenerative diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic potential. Alternatively, use of cord blood-derived stem cells is advantageous as it is easy to harvest, harmless to donor, ethical, ontogenetically primitive and can be stored in cord blood bank for years. Moreover, cord blood-derived stem cell transplantation is associated with reduced risk of developing graft versus host disease. However, from a single cord very limited number of stem cells could be isolated, which limits its clinical application. Our laboratory has developed a nanofiber-based ex-vivo human umbilical cord blood-derived stem cell expansion technology, which not only preserves stem cell characteristics also provides essential number of functional stem cells. Furthermore, we genetically modify nanofiber-expanded stem cells to enhance angiogenic/therapeutic potential for various degenerative diseases such as hind limb ischemia, myocardial ischemia, stroke-mediated ischemia, osteoporosis, Parkinson’s disease, and wound-healing. Current investigations use immunocompromised murine, rat and swine models for relevant studies. Molecular aspects of stem cell functionality are also being investigated in these animal models after cell-based therapy.
Reeva Aggarwal, MS. PhD student, IBGP program. 2008- present.
Suman Kanji, MS. PhD student, IBGP program, 2008-present
Jingwei Lu, MS. PhD student, MCDB program, 2008- present.
Nirmohi Mali, BS, under graduate student 2012- present.
Sridivya Kosuri, MBBS, postgraduate fellow 2012-present.
Megan E. Fisher, 12th Grade: High School graduate student, Upper Arlington High School, summer science project 2012.
Nnamdi Kalu, BS, undergraduate student, OSU, 2012-present.
Radhika Vazirani, High School graduate student, 2012- present.
Anupama Joseph, First year Medical student, OSU, 2012-present.
Human UCB-derived stem cells
Dental pulp-derived stem cells
Corneal stem cells; isolation, expansion, and genetic modification of stem cells
Differentiation; valuation of stem cell effects in preclinical model of ischemias, osteoporosis, Parkinson’s disease, wound healing
Determine molecular mechanisms of stem cell effect.
Aggarwal R, Lu J, Kanji S, Joseph M, Das M, Noble G, McMichael BK, Agarwal S, Hart RT, Sun Z, Lee BS, Jackson R, Mao HQ, Pompili VJ and Das H. Human umbilical cord blood-derived CD34+ stem cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. PLoS One 2012; 7(6): e39365.
Das M, Lu J, Joseph M, Aggarwal R, Kanji S, McMichael B, Lee BS, Agarwal S, Ray-Chaudhury A, Iwenofu, OH, Kuppusamy P, Pompili VJ, Jain MK and Das H. Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1β-induced arthritis. Current Molecular Medicine 2012; 12 (2): 113-125.
Lu J, Aggarwal R, Kanji S, Das M, Joseph M, Pompili VJ and Das H. Human Ovarian Tumor Cells Escape γδ T Cell Recognition Partly by Down Regulating Surface Expression of MICA and Limiting Cell Cycle Related Molecules. PLoS One 2011; 6(9): e23348. doi:10.1371/journal.pone.0023348.
Das H*, George JC, Joseph M, Das M, Abdulhameed N, Blitz, A, Sakthivel R, Mao HQ, Hoit BD, Kuppusamy P and Pompili VJ. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS ONE 2009; 4 (10): e7325. Doi:10. (*Corresponding author).
Das H*, Abdulhameed N, Joseph M, Sakthivel R, Mao HQ and Pompili VJ*. Ex-vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. Cell Transplantation 2009; 18: 305-318. (*Corresponding author).
Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, Majumder PK and Jain MK. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proceedings of the National Academy of Sciences 2006; 103: 6653-6658.
Das H, Sugita M and Brenner MB. Mechanisms of V1 T cell activation by microbial components. Journal of Immunology 2004, 172: 6578-6586.
Wang L, Kamath A, Das H, Li L and Bukowski JF. Antibacterial effect of human V2V2 T cells in vivo. Journal of Clinical Investigation 2001, 108:1349-1357.
Das H, Wang L, Kamath A and Bukowski JF. V2V2 T cell receptor-mediated recognition of aminobisphosphonates. Blood 2001, 98:1616-1618.
Das H, Groh V, Kuijl C, Sugita M, Morita C T, Spies T and Bukowski JF. MICA engagement by human V2V2 T cells enhances their antigen-dependent effector function. Immunity 2001, 15: 83-93.